{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:38Z","timestamp":1786119638687,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/coc.0b013e31820dbf56","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T08:15:00Z","timestamp":1299312900000},"page":"222-227","source":"Crossref","is-referenced-by-count":11,"title":["Activity of Thalidomide and Capecitabine in Patients With Advanced Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"35","author":[{"given":"Soo-Fan","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Huey","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Y.H.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Y.K.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian-Fong","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Pin","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","article-title":"Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.","volume":"14","author":"Pinter","year":"2009","journal-title":"Oncologist"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.","volume":"43","author":"Worns","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0046-8177(98)90205-2","article-title":"Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.","volume":"29","author":"Torimura","year":"1998","journal-title":"Hum Pathol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-2007-1007287","article-title":"Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations.","volume":"15","author":"Theise","year":"1995","journal-title":"Semin Liver Dis"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":"Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/02841860600702076","article-title":"Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma.","volume":"46","author":"Benjamin","year":"2007","journal-title":"Acta Oncologica"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/MEG.0b013e3283036740","article-title":"Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase III trial.","volume":"20","author":"Pinter","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.20821","article-title":"Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.","volume":"103","author":"Patt","year":"2005","journal-title":"Cancer"},{"key":"R14-4-20210128","first-page":"1696","article-title":"Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.","volume":"5","author":"Twelves","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6603956","article-title":"Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.","volume":"97","author":"Boige","year":"2007","journal-title":"Br J Cancer"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/annonc\/mdp010","article-title":"Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.","volume":"20","author":"Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2407-6-3","article-title":"Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.","volume":"6","author":"Park","year":"2006","journal-title":"BMC Cancer"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cncr.20368","article-title":"Oral capecitabine for treatment of HCC, cholangiocarcinoma, and gallbladder carcinoma.","volume":"101","author":"Patt","year":"2004","journal-title":"Cancer"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/02841860500341140","article-title":"Hepatocellular carcinoma-pathological complete response to oral capecitabine, megestrol and thalidomide.","volume":"45","author":"Richard Quek","year":"2006","journal-title":"Acta Oncol"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cncr.10384","article-title":"Construction of the Chinese University Prognostic Index for Hepatocellular Carcinoma and Comparison with the TNM Staging System, the Okuda Staging System, and the Cancer of the Liver Italian Program Staging System.","volume":"94","author":"Leung","year":"2002","journal-title":"Cancer"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification.","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3748\/wjg.v12.i43.6955","article-title":"Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.","volume":"12","author":"Chiou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R27-4-20210128","first-page":"2310","article-title":"Capecitabine for treatment of advanced hepatocellular carcinoma.","volume":"54","author":"von Delius","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201206000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:47:25Z","timestamp":1786042045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201206000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31820dbf56","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}